• English
    • Welsh
  • English 
    • English
    • Welsh
  • Login
Search DSpace:
  • Home
  • Research at Cardiff Met
  • Library Services
  • Contact Us
View item 
  • DSpace home
  • Cardiff School of Sport and Health Sciences
  • Sport Research Groups
  • View item
  • DSpace home
  • Cardiff School of Sport and Health Sciences
  • Sport Research Groups
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Should we treat soft tissue injuries with Actovegin?

Thumbnail
View/open
Final article (217.1Kb)
Author
Lee, Paul
Kwan, Alvin
Smith, Paul M.
Nokes, Len
Date
2016-11-16
Acceptance date
2016-11-09
Type
Article
Publisher
ECronicon Open Access
Metadata
Show full item record
Abstract
Actovegin is a biological drug produced from deproteinised hemodialysate of calf serum with over 50 years of history for its clinical use. There have been many in vitro studies to speculate its potential role and mechanism of action in cells; due to the nature of this drug and serum based culture techniques for most in vitro experiments, presumptuous conclusions and claims from these studies on performance enhancement should be cautiously interpreted. There have been well-designed human in vivo studies suggesting it does not enhance human performance, and has potentially good clinical applications to treat injuries, strokes and diabetes. Recently, evidence has emerged suggesting Actovegin has anti-inflammatory and anti-apoptotic effects on injured tissues; further clinical research is needed to define these effects. This article also provides a narrative review of Actovegin summarizing outcomes from recent publications.
Journal/conference proceeding
EC Orthapaedics;
Citation
Lee, P.Y.F., Kwan, A.P., Smith, P. and Nokes, L. (2016) 'Should we treat soft tissue injuries with Actovegin?', EC Orthopaedics, 4(4), pp.600-604.
URI
https://www.ecronicon.com/ecor/pdf/ECOR-04-0000102.pdf
http://hdl.handle.net/10369/8567
Description
Review article published open access in EC Orthopaedics available at https://www.ecronicon.com/ecor/pdf/ECOR-04-0000102.pdf
Rights
http://www.rioxx.net/licenses/all-rights-reserved
Sponsorship
Cardiff Metropolitan University (Grant ID: Cardiff Metropolian (Internal))
Collections
  • Sport Research Groups [1091]

Related items

Showing items related by title, author, subject and abstract.

  • Thumbnail

    Update on the Role of Actovegin in Musculoskeletal Medicine: A Review of the Past 10 Years 

    Brock, James; Golding, David; Smith, Paul M.; Nokes, Len; Kwan, Alvin; Lee, Paul Y.F. (Wolters Kluwer, 2018-01-15)
    Background: Actovegin is a biological drug with a controversial history of use in the treatment of sports injuries during the past 60 years. Particular concerns have been raised about its ergogenic potential to enhance ...
  • Thumbnail

    Actovegin equal to performance enhancing drug doping: fact or fiction? 

    Lee, Paul; Kwan, Alvin; Smith, Paul M.; Brock, James; Nokes, Len (OMICS International, 2016-10-23)
    Actovegin is a biological drug that has been used for the treatment of sports muscle injuries. Several in vitro studies have shed light on potential mechanisms of action and the drug has consistently demonstrated its ...

Browse

DSpace at Cardiff MetCommunities & CollectionsBy issue dateAuthorsTitlesSubjectsThis collectionBy issue dateAuthorsTitlesSubjects

My Account

Login

Statistics

Most Popular ItemsStatistics by CountryMost Popular Authors

DSpace software copyright © 2002-2015  DuraSpace
Contact us | Send feedback | Administrator